BTK inhibitors are preferred when patients have TP53 alterations [2]. It is well known that LPL/WM is often associated with autoimmune disorders, including autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia (ITP). Here, TP53 is linked to autoimmune thrombocytopenic purpura.